Catalyst
Slingshot members are tracking this event:
Arrowhead Pharma (ARWR) to Initiate Phase IIA Study in 2016 Evaluating ARC-AAT in Liver Disease Associated With a Genetic Disorder Causing Alpha-1 Antitrypsin Deficiency (AATD)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARWR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 06, 2016
Occurred Source:
http://www.businesswire.com/news/home/20160906005529/en
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase Iia, Arc-aat, Liver Disease, Alpha-1 Antitrypsin Deficiency
